SK
Therapeutic Areas
Solid Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SGT-003 | Duchenne muscular dystrophy (Duchenne) | Phase 1/2 |
| SGT-212 | Friedreich’s ataxia (FA) | Not Specified (Preclinical/Research) |
| SGT-501 | Catecholaminergic polymorphic ventricular tachycardia (CPVT) | Not Specified (Preclinical/Research) |
| SGT-601 | TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases | Not Specified (Preclinical/Research) |
Leadership Team at Solid Biosciences
BC
Bo Cumbo
President and CEO
KT
Kevin Tan
Chief Financial Officer
JH
Jessie Hanrahan, Ph.D.
Chief Regulatory & Preclinical Operations Officer
TH
Ty Howton
Chief Operating Officer
DG
Dr. Gabriel Brooks, M.D.
Chief Medical Officer
PH
Paul Herzich
Chief Technology Officer